Immunovaccine signs collaboration agreement with NCI
Immunovaccine signs collaboration agreement with NCI
Nov 11, 2009 (Datamonitor via COMTEX) -- Immunovaccine, a vaccine development company, has signed a collaborative agreement with the National Cancer Institute, or NCI, in Maryland, US.
The research collaboration involves formulating NCI's cancer vaccine antigens in DepoVax, Immunovaccine's vaccine enhancement system.
The research team at Immunovaccine will be collaborating with NCI investigator Jeffrey Schlom, head of the Immunotherapeutics group and chief of the Laboratory of Tumor Immunology & Biology.
According to Immunovaccine, DepoVax is a vaccine enhancement and delivery platform which has demonstrated ability to enhance the immunogenicity of antigens by creating a strong 'depot' at the site of immunization.
Marc Mansour, vice president of R&D at Immunovaccine, said: "NCI is a world leader in the study of cancer biology and cancer therapy and we look forward to seeing how our enhanced DepoVax delivery system improves immune responses to treat cancer."
http://www.datamonitor.com
Republication or redistribution, including by framing or similar means, is expressly prohibited without prior written consent. Datamonitor shall not be liable for errors or delays in the content, or for any actions taken in reliance thereon
| Cerimon Pharmaceuticals acquires European rights to pain patch< Prev | Next >Deloitte Recap Launches New Solution for Clinical Development |
|---|
Main Menu
FREE Daily Update!
